LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3418-3428

  Xu, Feng ^a   Liu, Jing ^a   Liu, Di ^a   Liu, Biao ^a   Wang, Min ^a   Hu, Zhiyuan ^b   Du, Xuemei ^c   Tang, Li ^a   He, Fuchu ^a,d,e  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY   (China)

^e TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; GAMMA INTERFERON; LSECTIN; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; HUMANS; INTERFERON-GAMMA; LECTINS, C-TYPE; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, VIRUS; TUMOR ESCAPE;

EID: 84903945401     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2690     Document Type: Article

References (41)

1. Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, et al. High frequencies of circulating melanoma-reactive CD8φ T cells in patients with advanced melanoma. Int J Cancer 2000;87:659-64.
2. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24: 175-208.
3. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
4. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
5. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10:294-8.
6. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
7. Waldmann TA. Effective cancer therapy through immunomodulation. Annu Rev Med 2006;57:65-81.
8. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
9. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004;165: 1853-63.
10. Kurte M, Lopez M, Aguirre A, Escobar A, Aguillon JC, Charo J, et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression ofMHCclass I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol 2004;173:1731-7.
11. Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS. Induction of a CD4φ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004;173:4352-9.
12. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4:43-9.
13. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3.
14. Sakaguchi S. Naturally arising CD4φregulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
15. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
16. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancerassociated immune suppression. Cancer Immunol Immunother 2002; 51:293-8.
17. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-3.
18. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 1999;96:11476-81.
19. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54:307-14.
20. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
21. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
22. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
23. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
24. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J 2005;272:6179-217.
25. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, et al. Galectin-9 increases Tim-3φdendritic cells and CD8φT cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008;181:7660-9.
26. Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, et al. Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node. J Biol Chem 2004;279:18748-58.
27. Tang L, Yang J, Liu W, Tang X, Chen J, Zhao D, et al. Liver sinusoidal endothelial cell lectin, LSECtin, negatively regulates hepatic T-cell immune response. Gastroenterology 2009;137:1498-508.e1-5.
28. Liu B, Wang M, Wang X, Zhao D, Liu D, Liu J, et al. Liver sinusoidal endothelial cell lectin inhibits CTL-dependent virus clearance in mouse models of viral hepatitis. J Immunol 2013;190:4185-95.
29. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001;Chapter 20:Unit 20.1.
30. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133: 1710-5.
31. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;68:869-77.
32. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
33. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
34. Li D, Liu W, Liu Z, Wang J, Liu Q, Zhu Y, et al. PRINCESS, a protein interaction confidence evaluation system with multiple data sources. Mol Cell Proteomics 2008;7:1043-52.
35. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8φ T-cell function in Hodgkin lymphoma patients. Blood 2006;108:2280-9.
36. Matsuzaki J, Gnjatic S,Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al.Tumor-infiltrating NY-ESO-1-specific CD8φT cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875-80.
37. Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011;186:5173-83.
38. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8φ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117: 3383-92.
39. Dominguez-Soto A, Aragoneses-Fenoll L, Martin-Gayo E, Martinez- Prats L, Colmenares M, Naranjo-Gomez M, et al. The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells. Blood 2007;109:5337-45.
40. Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 2003; 33:970-9.
41. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.